BACKGROUND: Dosing of tobramycin solution for inhalation (TSI) in cystic fibrosis (CF) patients was based on single-dose pharmacokinetic studies. This investigation was prompted by evidence of possible antibiotic accumulation in respiratory secretions with repeated dosing. The objectives were to evaluate whether tobramycin accumulates in respiratory secretions with repeated inhalation, compare total and biologically active tobramycin concentrations in CF sputum, and evaluate sputum induction for obtaining secretions for drug concentration assay. METHODS: Individuals with CF≥10 years of age were enrolled at the beginning of a course ofTSI, 300 mg twice daily for 28 days. Two study visits were conducted, 1-2 days and 24-28 days after initiation of TSI treatment. Induced sputum and expectorated sputum samples were collected for measurement of trough and peak tobramycin concentrations at each visit. Total tobramycin concentrations were measured by high-pressure liquid chromatography and bioactive concentrations by bioassay. RESULTS:Twenty participants completed the study. Trough concentrations were similar at visits 1 and 2, as were peak concentrations. Trough bioactive and total tobramycin concentrations were similar (mean ratio 1.2, 95% CI 0.56, 1.87), but peak bioactive concentrations were significantly lower than peak total concentrations (mean ratio 0.33, 95% CI 0.23, 0.44). Sputum induction was well tolerated. CONCLUSIONS: No evidence of significant drug accumulation in respiratory secretions with repeat dosing of TSI was seen. Peak bioactive concentrations, although lower than peak total concentrations, were still generally well within the bactericidal range. Sputum induction as a method for determining airway drug concentrations appears safe and feasible.
RCT Entities:
BACKGROUND: Dosing of tobramycin solution for inhalation (TSI) in cystic fibrosis (CF) patients was based on single-dose pharmacokinetic studies. This investigation was prompted by evidence of possible antibiotic accumulation in respiratory secretions with repeated dosing. The objectives were to evaluate whether tobramycin accumulates in respiratory secretions with repeated inhalation, compare total and biologically active tobramycin concentrations in CF sputum, and evaluate sputum induction for obtaining secretions for drug concentration assay. METHODS: Individuals with CF ≥10 years of age were enrolled at the beginning of a course of TSI, 300 mg twice daily for 28 days. Two study visits were conducted, 1-2 days and 24-28 days after initiation of TSI treatment. Induced sputum and expectorated sputum samples were collected for measurement of trough and peak tobramycin concentrations at each visit. Total tobramycin concentrations were measured by high-pressure liquid chromatography and bioactive concentrations by bioassay. RESULTS: Twenty participants completed the study. Trough concentrations were similar at visits 1 and 2, as were peak concentrations. Trough bioactive and total tobramycin concentrations were similar (mean ratio 1.2, 95% CI 0.56, 1.87), but peak bioactive concentrations were significantly lower than peak total concentrations (mean ratio 0.33, 95% CI 0.23, 0.44). Sputum induction was well tolerated. CONCLUSIONS: No evidence of significant drug accumulation in respiratory secretions with repeat dosing of TSI was seen. Peak bioactive concentrations, although lower than peak total concentrations, were still generally well within the bactericidal range. Sputum induction as a method for determining airway drug concentrations appears safe and feasible.
Authors: Claudia L Ordoñez; Noreen R Henig; Nicole Mayer-Hamblett; Frank J Accurso; Jane L Burns; James F Chmiel; Cori L Daines; Ronald L Gibson; Sharon McNamara; George Z Retsch-Bogart; Pamela L Zeitlin; Moira L Aitken Journal: Am J Respir Crit Care Med Date: 2003-09-11 Impact factor: 21.405
Authors: Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Margaret Rosenfeld; Ann Yunker; Nicole Hamblett; Frank Accurso; Mark Dovey; Peter Hiatt; Michael W Konstan; Richard Moss; George Retsch-Bogart; Jeffrey Wagener; David Waltz; Robert Wilmott; Pamela L Zeitlin; Bonnie Ramsey Journal: Am J Respir Crit Care Med Date: 2002-12-12 Impact factor: 21.405
Authors: Amsul Khanal; Ramankur Sharma; Timothy E Corcoran; Stephen Garoff; Todd M Przybycien; Robert D Tilton Journal: J Aerosol Med Pulm Drug Deliv Date: 2015-02-27 Impact factor: 2.849
Authors: Silvia M Caceres; Kenneth C Malcolm; Jennifer L Taylor-Cousar; David P Nichols; Milene T Saavedra; Donna L Bratton; Samuel M Moskowitz; Jane L Burns; Jerry A Nick Journal: Antimicrob Agents Chemother Date: 2014-09-02 Impact factor: 5.191
Authors: Tara Gallagher; Stefan Riedel; Joseph Kapcia; Lindsay J Caverly; Lisa Carmody; Linda M Kalikin; Junnan Lu; Joann Phan; Matthew Gargus; Miki Kagawa; Simon W Leemans; Jason A Rothman; Felix Grun; John J LiPuma; Katrine L Whiteson Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: Martina Koeva; Alina D Gutu; Wesley Hebert; Jeffrey D Wager; Lael M Yonker; George A O'Toole; Frederick M Ausubel; Samuel M Moskowitz; Diane Joseph-McCarthy Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: Marcel Stenvang; Morten S Dueholm; Brian S Vad; Thomas Seviour; Guanghong Zeng; Susana Geifman-Shochat; Mads T Søndergaard; Gunna Christiansen; Rikke Louise Meyer; Staffan Kjelleberg; Per Halkjær Nielsen; Daniel E Otzen Journal: J Biol Chem Date: 2016-10-26 Impact factor: 5.157
Authors: Sylvain Meylan; Caroline B M Porter; Jason H Yang; Peter Belenky; Arnaud Gutierrez; Michael A Lobritz; Jihye Park; Sun H Kim; Samuel M Moskowitz; James J Collins Journal: Cell Chem Biol Date: 2017-01-19 Impact factor: 8.116